The study is expected to begin this fall and is the producer’s first Canadian university partnership
.jpg)
CannTrust Holdings Inc. yesterday announced plans to collaborate with Hamilton Health Sciences and McMaster University on upcoming medical research studies.
The Vaughan, Ontario, based marijuana producer will be working with the Michael G. DeGroote Pain Clinic of Hamilton Health Sciences and McMaster University, and the Michael G. DeGroote Institute for Pain Research and Care of McMaster University on a range of upcoming randomized placebo controlled clinical trials (RCT).
The study, Cannabis Oil for Chronic Non-Cancer Pain Treatment (CONCEPT), is expected to begin this fall and is CannTrust’s first Canadian university partnership. It’s hoped the results will help health care practitioners and policy makers use cannabinoids for designing more effective, safer treatment protocols and public health policies. An analysis of CannTrust's 48,000 customer profiles indicates that pain is one of the primary reasons for utilizing medical cannabis.
Dr Ramesh Zacharias FRCS (C), Assistant Clinical Professor at McMaster University, Medical Director of the Michael G. DeGroote Pain Clinic and Principal Investigator in CONCEPT said: "CannTrust is an excellent partner for our research due to its consistent quality, standardized products and scientific approach. For research studies, we demand this same precision and attention to detail, so we appreciate that CannTrust is supporting the critical work conducted by our Centre."
The Michael G. DeGroote Pain Clinic at Hamilton Health Sciences is an interdisciplinary clinic with expertise in the management and treatment of chronic pain. As leaders in innovation and evidence based practices, the team works in collaboration with the patient, their family and referral sources. Its goal is to support adaptive changes to improve daily functioning, productivity and overall quality of life.
"We are honoured to begin this partnership as our organizations share very similar values. Also, it further advances our participation in research, innovation and customer education. We feel privileged by the role CannTrust can play in supporting these world-class researchers advance the understanding of medical cannabis," said Eric Paul, CEO, CannTrust.
